{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:48:10Z","timestamp":1779184090619,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.msard.2021.103363","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T17:01:00Z","timestamp":1635786060000},"page":"103363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The study of COVID-19 infection following vaccination in patients with multiple sclerosis"],"prefix":"10.1016","volume":"57","author":[{"given":"Fereshteh","family":"Ghadiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirreza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdorreza Naser","family":"Moghadasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2021.103363_bib0001","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult. Scler."},{"issue":"43","key":"10.1016\/j.msard.2021.103363_bib0002","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1016\/j.vaccine.2021.09.030","article-title":"Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV","volume":"39","author":"Ali Sahraian","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.msard.2021.103363_bib0003","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12883-020-01747-8","article-title":"Evidence of an increased prevalence of multiple sclerosis: a population-based study of Tehran registry during 1999-2018","volume":"20","author":"Almasi-Hashiani","year":"2020","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2021.103363_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102886","article-title":"COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM","volume":"51","author":"Alonso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103363_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","author":"Apostolidis","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.msard.2021.103363_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103078","article-title":"Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis","volume":"24","author":"Asplund Hogelin","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.msard.2021.103363_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102947","article-title":"Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study","volume":"52","author":"Barzegar","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103363_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.3599","article-title":"Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab","author":"Brill","year":"2021","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.103363_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9070773","article-title":"Multiple sclerosis, disease-modifying therapies and COVID-19: a systematic review on immune response and vaccination recommendations","volume":"9","author":"Cabreira","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.msard.2021.103363_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5603\/PJNNS.a2021.0031","article-title":"Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience","volume":"55","author":"Czarnowska","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"issue":"5","key":"10.1016\/j.msard.2021.103363_bib0011","doi-asserted-by":"crossref","first-page":"9","DOI":"10.15586\/aei.v49i5.105","article-title":"Investigating the association between allergic diseases and COVID-19 in 400 Iranian patients","volume":"49","author":"Darabi","year":"2021","journal-title":"Allergol. Immunopathol. (Madr.)"},{"issue":"2","key":"10.1016\/j.msard.2021.103363_bib0012","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/all.14452","article-title":"Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status","volume":"76","author":"Du","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.msard.2021.103363_bib0013","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12883-021-02218-4","article-title":"Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD","volume":"21","author":"Esmaeili","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2021.103363_bib0014","doi-asserted-by":"crossref","unstructured":"Gadani SP, Reyes-Mantilla M, Jank L, Harris S, Douglas M, Smith MD, Calabresi PA, Mowry EM, Fitzgerald KC, Bhargava P. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. medRxiv [Preprint]. 2021 Aug 25:2021.08.23.21262472. doi: 10.1101\/2021.08.23.21262472.","DOI":"10.1101\/2021.08.23.21262472"},{"key":"10.1016\/j.msard.2021.103363_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103045","article-title":"Attitudes toward vaccination in patients with multiple sclerosis: a report from Iran","volume":"53","author":"Ghadiri","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103363_bib0016","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis","author":"Jena","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.msard.2021.103363_bib0017","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2021.103363_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103153","article-title":"Outcomes of COVID-19 infection in multiple sclerosis and related conditions: one-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology consortium (NYCNIC)","volume":"55","author":"Klineova","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2021.103363_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9091031","article-title":"Prospective cohort study of the kinetics of specific antibodies to SARS-CoV-2 infection and to four SARS-CoV-2 vaccines available in Serbia, and Vaccine effectiveness: a 3-month interim report","volume":"9","author":"Lijeskic","year":"2021","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.msard.2021.103363_bib0020","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with Coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.103363_bib0021","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2021.103363_bib0022","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s10072-021-05373-1","article-title":"The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis","volume":"42","author":"Moghadasi","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103363_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103263","article-title":"Importance of T-cell response to COVID-19 vaccination in patients with multiple sclerosis treated by anti-CD20 therapies: new vaccines are required to be developed","volume":"56","author":"Naser Moghadasi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103363_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102120","article-title":"COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?","volume":"42","author":"Novi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103363_bib0025","first-page":"1","article-title":"Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies","author":"Prosperini","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103363_bib0026","doi-asserted-by":"crossref","unstructured":"Sabatino JJ, Mittl K, Rowles W, Mcpolin K, Rajan JV, Zamecnik CR, Dandekar R, Alvarenga BD, Loudermilk RP, Gerungan C, Spencer CM, Sagan SA, Augusto DG, Alexander J, Hollenbach JA, Wilson MR, Zamvil SS, Bove R. Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity. medRxiv [Preprint]. 2021 Sep 20:2021.09.10.21262933. doi: 10.1101\/2021.09.10.21262933. PMID: 34580672; PMCID: PMC8475959.","DOI":"10.1101\/2021.09.10.21262933"},{"key":"10.1016\/j.msard.2021.103363_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102195","article-title":"B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran","volume":"43","author":"Safavi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103363_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103363_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102968","article-title":"The outcome of a national MS-Covid-19 study: what the Turkish MS cohort reveals?","volume":"52","author":"Sen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103363_bib0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.msard.2019.06.009","article-title":"Multiple sclerosis national registry system in Iran: validity and reliability of a minimum data set","volume":"33","author":"Shahin","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103363_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102800","article-title":"COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review","volume":"50","author":"Sharifian-Dorche","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2021.103363_bib0032","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and Coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103363_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2021.103363_bib0034","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","author":"van Lierop","year":"2021","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2021.103363_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ACI.0000000000000699","article-title":"Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions","volume":"21","author":"Wakabayashi","year":"2021","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2021.103363_bib0036","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/CPJ.0000000000001088","article-title":"COVID-19 vaccination in patients with multiple sclerosis on disease-modifying therapy","volume":"11","author":"Wolf","year":"2021","journal-title":"Neurol. Clin. Pract."},{"issue":"4","key":"10.1016\/j.msard.2021.103363_bib0037","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2020.08.008","article-title":"Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study","volume":"146","author":"Yang","year":"2020","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:35:47Z","timestamp":1735576547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":37,"alternative-id":["S2211034821006301"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103363","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The study of COVID-19 infection following vaccination in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103363"}}